Chongqing Natural Pharmaceuticals, Tianjin Children's Pharmaceuticals, Guangzhou Huayu Pharmaceuticals and other 8 pharmaceutical companies went bankrupt

Dandelion small editor query, recently, there are 8 pharmaceutical companies due to debt and other issues, into bankruptcy, liquidation procedures, Chongqing Natural Pharmaceutical Sinco: 230 millionDecember 26, 2019, the applicant Chongqing Natural Pharmaceutical Co., Ltdon the grounds that it can not recover receivables and can not obtain financing, the existing assets of the enterprise is not enough to pay off all the debts on the grounds that the bankruptcy reorganizationit is understood that Chongqing Natural Pharmaceutical Co, Ltdthrough the restructuring of state-owned enterprises was founded in June 2001, is a collection of scientific research, production and sales as a whole, to produce Chinese medicine tablets, formula particles-based integrated pharmaceutical enterprises2017, the applicant Chongqing Natural Pharmaceutical Co., Ltdhas been sued to the court several times for disputes with Standard Chartered Bank (China) Co., LtdChongqing Branch, Chongqing Cultural Guarantee Company, Chongqing New Century Microfinance Company, Tao Jian and other enterprises and natural persons over loans, equity capital increase, purchase and sale contracts, etc., involving more than 100 million yuan of outstanding funds, resulting in enterprises unable to obtain financingin addition, chongqing natural pharmaceutical Co, Ltdpart of the debtor bankruptcy, affecting the company's large number of receivables can not be recovered, resulting in the company's liquidity difficultiesthe applicant's self-examination, as of December 31, 2019, the total book assets of the applicant Chongqing Natural Pharmaceutical Co., Ltd(mainly accounts receivable, biological assets and intangible assets, etc.) amounted to RMB 96429503.09, and liabilities (mainly short-term loans, other payables, employee compensation payable and taxes, etc.) totalled RMB 23072027.48II, Tianjin Children's Pharmaceutical Sini, 32 years old pharmaceutical enterprises, due to 200 million yuan loan can not repay bankruptcy
January 2, 2020, the applicant growth power (China) Co., Ltd on the grounds that it can not pay off the debts due, and obviously lack of liquidity, on the grounds that the court applied for the bankruptcy liquidation of Tianjin Children's Pharmaceutical Co., Ltd Tianjin Children's Pharmaceutical Co., Ltd recognizes that the applicant has a claim on it because it lacks liquidity to the debt and does not dispute the applicant's bankruptcy liquidation Tianjin Children's Pharmaceutical Co., Ltd was established on November 21, 1988, the company's headquarters in Tianjin Airport Economic Zone, the production base is located in Binhai New Area Dagang Petrochemical Industrial Park Jinhui Road, covers an area of 175,000 square meters, and under the tianjin Children's Pharmaceutical Co., Ltd., Growth Power (Tianjin) Biotech Co., Ltd., Tianjin Children's Health Bioengineering Co., Ltd three subsidiaries, currently mainly produced and operated Granules (including penicillin, cephalosporins), tablets (including cephalosporins), syrups, combination serotonin manufacturing, processing; lean brand weight loss capsules, peatbrand edgy tablets, Peiyu brand zieium return tablets commissioned production; and rely on children's drugs research and development, production and sales of children-related reference water and health products approval: on May 1, 2016, Growth Dynamics (China) Co., Ltd signed the "Maximum Borrowing Contract" with Tianjin Children's Pharmaceuticals, agreeing that between May 1, 2016 and December 31, 2020, the applicant will be submitted to the respondent To provide a loan within the amount of 200 million yuan, the two sides in January 15 each year to check the previous year's borrowing amount and make a reconciliation letter, confirmed by both parties and signed a letter, the reconciliation letter issued, the respondent should be in accordance with the amount recognized in it, within one month to repay the applicant since then, the two sides have repeatedly reconciled and issued a "reconciliation letter." On June 4, 2018, the two parties signed an advance agreement, which stipulates that the applicant will advance the employee's salary and other expenses for the respondent from July 2018 On October 30, 2019, the respondent issued a written statement to the applicant stating that, as of September 30, 2019, the respondent owed the applicant RMB 123818889.57 yuan after the reconciliation between the two parties, and that the arrears had been overdue for a long time, and the respondent had been unable to repay the arrears due to operational difficulties, and was still unable to repay the debt , according to the balance sheet submitted by the respondent, as at September 30, 2019, the total assets of the respondent were RMB417545933.14, the total liabilities amounted to RMB489407206.66 and the owner's equity was RMB 71861273.52 III, North China Pharmaceutical Group Huasu Chemical Co., Ltd October 31, 2019, the applicant North China Pharmaceutical Group Co., Ltd on the grounds that the respondent North China Pharmaceutical Group Huasu Chemical Co., Ltd can not pay off the debts due and obvious lack of liquidity on the grounds that the court applied to North China Pharmaceutical Group Huasu Chemical Co., Ltd for bankruptcy liquidation court found that the applicant North China Pharmaceutical Group Co., Ltd claimed that as of August 2019, the respondent still owed the applicant 8964909.47 yuan, mainly production and operation loans and loans to solve the historical legacy of the security debt problem, as well as interest charges the respondent, North China Pharmaceutical Group Huasu Chemical Co., Ltd., was established on August 9, 1996 audited by the Hebei branch of Lianda Accounting Firm (Special General Partnership), as of December 31, 2018, the book assets of the respondent, Huasu Chemical Co., Ltd., North China Pharmaceutical Group, amounted to RMB82,029.78, with total liabilities of RMB43,155,755.13, net assets of RMB 43,073,725.35, and an asset-liability ratio of RMB52,609.86 4, North China Pharmaceutical Group Huatai Pharmaceutical Co., Ltd October 31, 2019, the applicant North China Pharmaceutical Group Co., Ltd on the grounds that the respondent North China Pharmaceutical Group Huatai Pharmaceutical Co., Ltd can not pay off the debts due and obvious lack of liquidity on the grounds that the court applied to North China Pharmaceutical Group Huatai Pharmaceutical Co., Ltd for bankruptcy liquidation the court to find out: the applicant North China Pharmaceutical Group Co., Ltd claims that as of August 2019 the applicant still owes the applicant 24490623.97 yuan, mainly production and operation of loans and to solve the historical legacy of the debt problem of the formation of loans and interest charges Huatai Pharmaceutical Co., Ltd., a North China Pharmaceutical Group, was established on March 6, 1996 audited by the Hebei branch of Lianda Accounting Firm (Special General Partnership), as of December 31, 2018, the book assets of huatai Pharmaceutical Co., Ltd., the respondent, North China Pharmaceutical Group, amounted to RMB37,971.53, with total liabilities of RMB69,186,314.43, total owner's equity of RMB 69,148,342.90, with an asset-liability ratio of RMB182,205.76 5, Guangzhou Huayu Pharmaceutical Co., Ltd., Court on June 4, 2019 to accept the Guangdong Pharmaceutical Company's application for Guangzhou Huayu Pharmaceutical Co., Ltd mandatory liquidation the liquidation group to investigate the property and debt of Huayu Company, Huayu Company has no property, books, important documents, during the creditor's rights declaration period, a total of 1 creditor wu Qiugui declared the claim to the liquidation group, after the liquidation group review, the claim was confirmed The liquidation group sent letters to Huayu Company and its shareholders Guangdong Pharmaceutical Company, Hong Kong Wee Gao Pharmaceutical Co., Ltd., Guangzhou Tianhe District Industrial Corporation informing that if Huayu Company has no property, books, important documents, etc., and that the status quo of the whereabouts of the respondent's persons are unknown, the controlling shareholder and the actual controller may have liquidation responsibilities and risks After the liquidation group explains the relevant responsibilities to the shareholders separately, it is still unable to liquidate, and the liquidation group applies for the termination of the compulsory liquidation procedure 6, Yunnan Teng Pharmaceutical Biotech Co., Ltd Yunnan Teng Pharmaceutical Biotech Co., Ltd was established on June 01, 2007, registered in Teng Chong City, Yunnan Province, Teng Yue Town Business scope includes biotechnology development, plant cultivation, skin, mucous membrane sanitary products (anti- and anti-bacterial lotions), skin care, hair-based cosmetics and tableware detergent production and sales December 20, 2019, Yunnan Teng Pharmaceutical Biotech Co., Ltd mandatory liquidation group submitted to this court "on the people's court to order the termination of the liquidation procedures of Yunnan Teng Pharmaceutical Biotech Co., Ltd., requiring the termination of Yunnan Teng Pharmaceutical Biotech Co., Ltd mandatory liquidation procedures." 7, Zhejiang Shuangxi Pharmaceutical Co., Ltd According to public information, the company is located in huzhou Development Zone, covers an area of more than 5000 square meters, of which office space of more than 1000 square meters, logistics center room area of more than 4000 square meters The company's drug procurement, sales, storage of all the use of semi-automated computer management, sales in 2008 exceeded 200 million yuan, and strive to 2009 sales reached 500 million yuan Court Executive Board in the implementation of a series of cases involving Zhejiang Shuangxi Pharmaceutical Co., Ltd as the executed person, found that Zhejiang Shuangxi Pharmaceutical Co., Ltd can not pay off the debts due, and the assets are not enough to pay off all the debts, so transferred to the bankruptcy review, while the creditor State Pharmaceutical Holdings Lishui Co., Ltd also filed for bankruptcy liquidation application with the Court On October 16, 2019, the Court decided to accept the bankruptcy liquidation case of Zhejiang Shuangxi Pharmaceutical Co., Ltd Court found that the first creditors' meeting in the bankruptcy liquidation case of Zhejiang Shuangxi Pharmaceutical Co., Ltd was held by post and written vote on January 10, 2020 During the filing period of the claim in this case, a total of 18 creditors declared their claims to the administrator, and after examination by the administrator, verification at the first creditors' meeting and the ruling of the Court, the amount of claims of 18 creditors has been confirmed at present to be RMB458204529.52 Another survey by the administrator, the respondent's actual assets are mainly bank deposits of 176.54 yuan In summary, Zhejiang Shuangxi Pharmaceutical Co., Ltd has total assets of 176.54 yuan and total liabilities of 458204529.52 yuan, as of April 1, 2020 has incurred bankruptcy costs of 3459 yuan according to the , the administrator, on the grounds that the property of the respondent Zhejiang Shuangxi Pharmaceutical Co., Ltd is not sufficient to pay off the bankruptcy costs and does not have the conditions for reorganization and settlement, brought the court to declare Zhejiang Shuangxi Pharmaceutical Co., Ltd bankrupt and terminate the bankruptcy proceedings of Zhejiang Shuangxi Pharmaceutical Co., Ltd 8, Guangdong Pharmaceutical Company November 21, 2019, Guangdong Pharmaceutical Company Administrator (hereinafter referred to as the Administrator) applied to the Court, said that after the liquidation of Guangdong Pharmaceutical Company, Guangdong Pharmaceutical Company is now unable to pay its debts due, is in solvent, there is no property to distribute, and requested the court to rule to declare Guangdong Pharmaceutical Company bankrupt and terminate the bankruptcy liquidation proceedings of Guangdong Pharmaceutical Company The Court of found that, after a special audit, as of December 31, 2018, the book assets of Guangdong Pharmaceutical Company was 68855.66 yuan and its book liability was RMB20866616.05 In the course of liquidation, on November 6, 2019, the Court decided to confirm the claims of nine creditors, including the Guangzhou Yunshan Branch of Industrial and Commercial Bank of China Co., Ltd., with a total amount of 51330061.94 yuan According to the investigation by the administrator, the total bankruptcy property of Guangdong Pharmaceutical Company was RMB 98,224.54 After priority payment of bankruptcy expenses, Guangdong Pharmaceutical Company has no property to distribute declared the bankruptcy of Guangdong Pharmaceutical Company and ended the bankruptcy proceedings of Guangdong Pharmaceutical Company (original title: 8 pharmaceutical companies went bankrupt)